AstraZeneca PLC (NASDAQ: AZN) closed the day trading at $71.79 down -0.84% from the previous closing price of $72.40. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 4382719 shares were traded. AZN stock price reached its highest trading level at $72.17 during the session, while it also had its lowest trading level at $71.43.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ratios:
For a better understanding of AZN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 138.97. For the most recent quarter (mrq), Quick Ratio is recorded 0.70 and its Current Ratio is at 0.90. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.77.
Upgrades & Downgrades
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 227.96B and an Enterprise Value of 253.00B. As of this moment, AstraZeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 47.61, and their Forward P/E ratio for the next fiscal year is 16.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.04 while its Price-to-Book (P/B) ratio in mrq is 6.22. Its current Enterprise Value per Revenue stands at 5.77 whereas that against EBITDA is 22.97.
Stock Price History:
Over the past 52 weeks, AZN has reached a high of $76.56, while it has fallen to a 52-week low of $52.65. The 50-Day Moving Average of the stock is 72.43, while the 200-Day Moving Average is calculated to be 66.01.
Shares Statistics:
Over the past 3-months, AZN traded about 4.04M shares per day on average, while over the past 10 days, AZN traded about 3.64M shares per day. A total of 3.10B shares are outstanding, with a floating share count of 2.99B. Insiders hold about 0.50% of the company’s shares, while institutions hold 17.90% stake in the company. Shares short for AZN as of Apr 27, 2023 were 5.81M with a Short Ratio of 4.67M, compared to 3.79M on Mar 30, 2023.
Dividends & Splits
AZN’s forward annual dividend rate is 2.44, up from 2.90 a year ago. Against a Trailing Annual Dividend Yield of 4.01%, it implies a Forward Annual Dividend Yield of 1.95%. The stock’s 5-year Average Dividend Yield is 2.80. The current Payout Ratio is 0.00% for AZN, which recently paid a dividend on Mar 26, 2023 with an ex-dividend date of Feb 22, 2023. Stock splits for the company last occurred on Jul 26, 2015 when the company split stock in a 2:1 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of $0.91 for the current quarter, with a high estimate of $1.04 and a low estimate of $0.83, while EPS last year was $0.86. The consensus estimate for the next quarter is $0.95, with high estimates of $1 and low estimates of $0.88.
Analysts are recommending an EPS of between $3.75 and $3.64 for the fiscal current year, implying an average EPS of $3.69. EPS for the following year is $4.31, with 4 analysts recommending between $4.63 and $3.96.
Revenue Estimates
4 analysts predict $11.25B in revenue for the current quarter. It ranges from a high estimate of $11.69B to a low estimate of $10.82B. As of the current estimate, AstraZeneca PLC’s year-ago sales were $10.77B, an estimated increase of 4.40% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $11.7B, an increase of 7.20% over than the figure of $4.40% in the same quarter last year. There is a high estimate of $12.47B for the next quarter, whereas the lowest estimate is $11.35B.
A total of 6 analysts have provided revenue estimates for AZN’s current fiscal year. The highest revenue estimate was $45.94B, while the lowest revenue estimate was $44.87B, resulting in an average revenue estimate of $45.53B. In the same quarter a year ago, actual revenue was $44.35B, up 2.70% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $49.72B in the next fiscal year. The high estimate is $50.44B and the low estimate is $48.79B. The average revenue growth estimate for next year is up 9.20% from the average revenue estimate for this year.
